Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 5, 2001, Pages 789-824

  Smith, H J ^a   Nicholls, P J ^a   Simons, C ^a   Le Lain, R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

17 Hydroxysteroid dehydrogenase (17 HSD); 17,20 Lyase (P450 17); 5 Steroid reductase (5 SR); Androgens; Aromatase (P450AROM); Breast cancer; Hormone dependent cancers; LHRH antagonists; Oestrogen sulfatase; Oestrogens; Prostate cancer; RAMBA

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; AROMATASE; CALCITRIOL; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ESTROGEN; FORMESTANE; GLUCOCORTICOID; GONADORELIN; GONADORELIN AGONIST; HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; ISOENZYME; LETROZOLE; RALOXIFENE; RETINOIC ACID; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE; STEROID HORMONE; SULFATASE; TAMOXIFEN; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; TOREMIFENE; UNINDEXED DRUG;

BREAST CANCER; CANCER; CANCER GROWTH; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG METABOLISM; DRUG TARGETING; HORMONE METABOLISM; HUMAN; HUMAN TISSUE; PROSTATE CANCER; REMISSION; REVIEW; SIDE EFFECT; STEROIDOGENESIS; TESTOSTERONE SYNTHESIS;

EID: 0035019952     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.5.789     Document Type: Review

References (212)

1. Breast cancer management: Science and care together
2. Management of early breast cancer
3. Mammography and breast cancer screening
4. Development of anti-oestrogens and their use in breast cancer: Memorial award lecture
5. Antioestrogens: Mechanism of action and resistance in breast cancer
6. Endometrial carcinoma associated with breast cancer: Low incidence with tamoxifen use
7. New endocrine therapies for breast cancer
8. Inhibitory cross-talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity in agonist-and antagonist-occupied progestin receptors
9. AROMe
10. The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds
11. Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer
12. Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome-P450
13. A site-directed mutagenesis study of human placental aromatase
14. Structure-activity relationships for non-steroidal inhibitors of aromatase
15. Aromatase inhibitors and breast cancer
16. Aminoglutethimide and ketoconazole: Historical perspectives and future prospects
17. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer
18. In vitro and in vivo studies demonstrating potent and selective oestrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A
19. Inhibition of aromatase in vitro and in vivo by aromatase inhibitors
20. Aromatase inhibitors: A dose-response effect?
21. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
22. Arimidex: A potent and selective fourth-generation aromatase inhibitor
23. Inhibition of the in vivo conversion of androstenedione to oestrone by the aromatase inhibitor vorozole in healthy postmenopausal women
24. Phase 1 and endocrine study of exemestane (PCE 24304), a new aromatase inhibitor, in postmenopausal women
25. From programme sanction to clinical trials: A partial view of the quest for Arimidex™, a potent selective inhibitor of aromatase
26. Enzyme inhibitors as drugs: From design to the clinic
27. AROM) inhibitors
28. Drug and hormone interactions of aromatase inhibitors
29. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
30. Synthesis and structure-activity relationships of 6-phenylaliphatic-substituted C-19 steroids having a 1,4-diene, 4,6-diene or 1,4,6-triene structure as aromatase inhibitors
31. New selective nonsteroidal aromatase inhibitors. Synthesis and inhibitory activity of 2,3 or 5-(alphaazoylbenzyl)-1H-indoles
32. Design and synthesis of a new type of nonsteroidal human aromatase inhibitor
33. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
34. Cross-resistance to different aromatase inhibitors in breast cancer treatment
35. Breast tumour aromatase: Functional role and transcriptional regulation
36. 2
37. Nonsteroidal anti-inflammatory drugs and breast cancer
38. Concentrations of estrone, estradiol and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients
39. Importance of estrogen sulfates in breast cancer
40. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta-5-steroids in the ZR-75-1 human breast cancer cell line
41. Immunological consequences of inhibiting dehydroepiandrosterone sulfatase in vivo
42. Enhanced plasma DHEAS, brain acetylcholine and memory mediated by steroid sulfatase inhibition
43. The sulfatase gene family
44. Steroid sulfatase inhibitors
45. Human placental steryl sulfatase: Enzyme purification, production of antisera and immunoblotting reactions with normal and sulfatase-deficient patients
46. A novel amino acid modification in sulphatases that is defective in multiple sulphatase deficiency
47. Structure of the lysosomal sulfatase
48. Crystal structure of human arylsulfatase A: The aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis
49. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates
50. Inhibition of estrone sulfatase in human placenta and human breast carcinoma
51. Action of danazol on the conversion of estrone sulphate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells
52. Estrone sulfamates: Potent inhibition of estrone sulfatase with therapeutic potential
53. The development of A-ring modified analogues of oestrone-3-O-sulfamate as potent steroid sulphatase inhibitors with reduced oestrogenicity
54. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase
55. Development of potent non-estrogenic estrone sulfatase inhibitors
56. 17α-Alkyl- or 17α-substituted benzyl-17β-estradiols: A new family of oestrone sulphatase inhibitors
57. Potent inhibition of steroidal sulfatase activity by 3-O-sulfamate 17α-benzyl (or 4′-tertbutylbenzyl) estra-1,3,5(10)-trienes: Combination of two substituents at positions C3 and 17α of estradiol
58. Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors
59. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by non-steroidal (p-O-sulfamoyl)-N-alkanoyl tyramines
60. Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates
61. In vivo activity of 4-methylcoumarin-7-O-sulfamate, a nonsteroidal, nonestrogenic steroid sulfatase inhibitor
62. In vivo inhibition of estrone sulfatase and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE
63. Status of aromatase inhibitors in relation to other breast cancer treatment modalities
64. Characteristics of human Types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition
65. 17β-Hydroxysteroid dehydrogenase: Isozymes and mutations
66. 17β-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family: Nomenclature and main characteristics of the 17 HSD/KSR enzymes
67. Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA
68. Characterisation of cDNAs for human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17: Evidence of two mRNA species with distinct 5′ termini in human placenta
69. Expression cloning and characterisation of human 17β-hydroxysteroid dehydrogenase Type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity
70. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3
71. Regulation of estradiol 17β-hydroxysteroid dehydrogenase in breast tissue - The role of growth factors
72. Aromatase activity in normal breast and breast tumor tissue: In vivo and in vitro studies
73. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex-hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
74. The relationship between 17β-hydroxysteroid dehydrogenase and breast tumour site and size
75. The role of tissue steroids in regulating aromatase and estradiol 17β-hydroxysteroid dehydrogenase activities in breast and endometrial cancer
76. A possible mechanism for increased breast cell-proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity
77. Estradiol synthesis from estrone in malignant breast epithelial cells-studies on a high affinity, 80KDa form of estradiol dehydrogenase
78. A comparison of the in vivo uptake and metabolism of H-3 estrone and H-3 estradiol by normal breast and breast tumour tissues in postmenopausal women
79. Inhibition of 17β-hydroxysteroid dehydrogenase activity in human endometrium by adrenal androgens
80. 17β-Hydroxysteroid oxidoreductase activity in intact cells significantly differs from classical enzymology analysis
81. 17β-Hydroxysteroid dehydrogenases in normal mammary epithelial cells and breast tissue
82. 17β-Hydroxysteroid dehydrogenase Type 1 and Type 2 in human breast carcinoma: A correlation to clinicopathological parameters
83. Steroidal regulation of oestradiol 17β-dehydrogenase - Activity of the human breast cancer cell-line MCF-7
84. The role of cytokines and sulfatase inhibitors in regulating estrogen synthesis in breast tumours
85. Human 17β-hydroxysteroid Type 1 and Type 2 isoenzymes have opposite activities in cultured cells and characteristic cell and tissue specific expression
86. 17β-Hydroxysteroid dehydrogenase gene-expression in human breast cells - Regulation of expression by a progestin
87. Intracellular regulation of 17β-hydroxysteroid dehydrogenase Type 1 catalytic activity in A431 cells
88. 17β-Hydroxysteroid dehydrogenase: Inhibitors and inhibitor design
89. Synthesis of 16-(bromoalkyl)-estradiols having inhibitor effect on estradiol 17β-hydroxysteroid dehydrogenase (17β-HSD Type 1)
90. Inhibition of oestrone sulfatase and 17β-hydroxysteroid dehydrogenase by antioestrogens
91. A 6β-(thiaheptanamide) derivative of oestradiol as inhibitor of 17β-hydroxysteroid dehydrogenase Type 1
92. Synthesis and evaluation of oestradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitor of 17β-hydroxysteroid dehydrogenase Type 1 without estrogenic activity
93. Overview of a rational approach to design Type 1 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: Chemical synthesis and biological evaluation
94. Steroidal spiro-γ-lactones that inhibit 17β-hydroxysteroid dehydrogenase activity in human placental microsomes
95. Spironolactone-related inhibitors of Type II 17β-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities and antiproliferative activities
96. Effects of Org OD14 (Livial®) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells
97. Naringenin: A weakly estrogenic bioflavanoid that exhibits antiestrogenic activity
98. In vitro bioassays of non-steroidal phytoestrogens
99. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture
100. Inhibitors of human and rat testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD) as potential agents for prostatic cancer
101. Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavanoids
102. Structure of human oestrogenic 17β-hydroxysteroid dehydrogenase at 220Å resolution
103. + identifies two principal targets for design of inhibitors
104. + in 17β-hydroxysteroid hydrogenase
105. Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17β-hydroxysteroid dehydrogenase- C-18/C-19 steroid discrimination and enzyme-induced strain
106. Crystallisation and preliminary crystal structure of the complex 17β-hydroxysteroid dehydrogenase with a dual-site inhibitor
107. Cancer statistics, 1993
108. The concept of evolution in the pathogenesis and treatment of prostate cancer
109. Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique
110. Early detection of prostate cancer: Classic aspects of prostate cancer pathology
111. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
112. Steroid 5-alpha-reductase - 2 genes 2 enzymes
113. Management of hormonal treatment effects
114. Androgen deprivation with radiation-therapy compared with radiation-therapy alone for locally advanced prostatic-carcinoma - A randomized comparative trial of the radiation-therapy oncology group
115. New methods of endocrine management of prostatic cancer
116. Discovery of a novel, potent and orally-active non-peptide antagonist of the human luteinizing hormone - Releasing hormone (LHRH) receptor
117. Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist
118. Investigation of the 4-O-alkylamine substituent of non-peptide quinolone. GnRH receptor antagonists
119. Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides
120. The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro
121. Finasteride - A review of its use in male pattern hair loss
122. Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCaT cells
123. Finasteride - An update and review
124. Combined finasteride and flutamide therapy in men with advanced prostate cancer
125. Combination finasteride and flutamide in advanced carcinoma of the prostate - Effective therapy with minimal side-effects
126. Pharmacological options in the treatment of benign prostatic hyperplasia
127. Steroidal and nonsteroidal inhibitors of 5-alpha-reductase
128. Inhibitors of 5-alpha-reductase
129. 17α and 5α-steroid reductase
130. Human prostatic steroid 5-alpha-reductase isoforms a comparative study of selective inhibitors
131. Mechanism-based inhibition of human steroid 5 alpha-reductase by finasteride: Enzyme-catalyzed formation of NADP-dihydrofinasteride, potent bisubstrate analog inhibitor
132. Inhibition of human steroid 5 alpha reductase Type I and II by 6-aza-steroids: Structural determinants of one-step vs. two-step mechanism
133. Cloning, expression and characterisation of rhesus macaque types 1 and 2 5α-reductase: Evidence for mechanism-based inhibition by finasteride
134. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia
135. Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat
136. Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073)
137. Effects of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma
138. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes
139. The effect of finasteride in men with benign prostatic hyperplasia
140. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia
141. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia
142. 4-aza-3-oxo-5-alpha-androst-1-ene-17-beta-N-aryl-carboxamides as dual inhibitors of human type-1 and type-2 steroid 5-alpha-reductase - Dramatic effect of N-aryl substituents on type-1 and type-2 5-alpha reductase inhibitory potency
143. Mechanism of time-dependent inhibition of 5-alpha-reductase by delta(1)-4-azasteroids - Towards perfection of rates of time-dependent inhibition by using ligand-binding energies
144. FCE 28260, a new alpha-reductase inhibitor: In vitro and in vivo effects
145. MK386: A potent, selective inhibitor of the human Type 1 5-alpha reductase
146. Structure-activity-relationships for inhibition of type-1 and type-2 human 5-alpha-reductase and human adrenal 3-beta-hydroxy-delta(5)-steroid dehydrogenase 3-keto-delta(5)-steroid isomerase by of the C17 substituent
147. Episteride is a selective and specific uncompetitive inhibitor of human steroid 5-alpha-reductase isoform-2 J
148. The mechanism of episteride against benign prostatic hyperplasia
149. 3-Carboxy-20-keto steroids are dual uncompetitive inhibitors of human steroids 5 alpha-reductase types 1 and 2
150. Tissue distribution and kinetic characteristics of rat steroid 5-alpha-reductase isozymes - Evidence for distinct physiological functions
151. The development of non-steroidal dual inhibitors of both human 5 alpha-reductase isozymes
152. 5-Alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro
153. Novel steroid 5-alpha-reductase inhibitor FK143 - Its dual inhibition against the 2-isoforms and its effect on transcription of the isozyme genes
154. FK143, a novel nonsteroidal inhibitor of steroid 5-alpha-reductase. 2. In-vivo effects on rat and dog prostates
155. Inhibition of rat prostate carcinogenesis by a 5 alpha-reductase inhibitor, FK143
156. Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5α-reductase, in healthy volunteers
157. Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5α-reductase inhibitor 4-[3-[3-[bis (4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyric acid in rats
158. Tissue distribution kinetics of a new nonsteroidal 5α-reductase inhibitor, 4-[3-[3-[bis(4-isobutylphenyl) methylamino]benzoyl]-1H-indol-1-yl] butyric acid
159. Effects of a new non-steroidal 5α-reductase inhibitor, FK143, on the prostate gland in beagle dogs
160. FR146687, a novel steroid 5 alpha-reductase inhibitor: In vitro and in vivo effects on prostates
161. Benzophenonecarboxylic and indolecarboxylic acids - Potent type-2 specific inhibitors of human steroid 5-alpha-reductase
162. Finasteride -An update of its use in the management of symptomatic benign prostatic hyperplasia
163. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years
164. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study
165. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
166. Prostate carcinoma
167. Design of the Prostatic Cancer Prevention Trial (PCPT)
168. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
169. The V89L polymorphism in the 5α-reductase Type 2 gene and risk of prostate cancer
170. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5α-reductase during prostate cancer progression
171. 17a-Hydroxylase/ 17,20-lyase
172. Inhibitors of cytochrome P450 (17 alpha) (17 alpha-hydroxylase/C-17,20 lyase)
173. Inhibitors of 17α-hydroxylase/17,20-lyase (CYP 17): Potential agents for the treatment of prostate cancer
174. Steroid synthesis inhibition by ketoconazole: Sites of action
175. Imidazole antimycotics: Selective inhibitors of steroid aromatization and progesterone hydroxylation
176. Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs
177. From 14α-demethylase inhibitors in fungal cells to androgen and oestrogen biosynthesis inhibitors in mammalian cells
178. R75251, a new inhibitor of steroid synthesis
179. Retinoic acid and cytochrome P-450
180. Experimental studies with liarozole (R75251): An anti-tumoral agent which inhibits retinoic acid breakdown
181. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo
182. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
183. Synthesis of Liazal (TM), a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology
184. Metabolism of all-trans, 9-cis and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P-450 and mechanism-based inhibition of retinoid oxidation by citral
185. Metabolism of all-trans-retinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy- to 4-keto-retinoic acid
186. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans retinoic acid
187. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats
188. Liarozole fumarate (R85246): A novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
189. Phase II study of liarozole in advanced non-small cell lung cancer
190. Early clinical experience with Liarozole (Liazal™) in patients with progressive prostate cancer
191. Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomised trial versus cyproterone acetate
192. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
193. Liarozole acts synergistically with 1 alpha, 25-dihydroxyvitamin D-3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
194. Effect of P450 isozyme-selective inhibitors on in-vitro metabolism of retinoic acid by rat hepatic microsomes
195. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoid effects in rodents
196. 1-[(Benzofuran-2-yl)-phenylmethyl] imidazoles as inhibitors of 17α-hydroxylase:17,20-lyase (P450 17): Species and tissue differences
197. Some 1-[(benzofuran-2-yl)methyl]-imidazoles as inhibitors of 17α-hydroxylase; 17-20-lyase (P450 17) and their specificity patterns
198. Imidazole substituted diphenyls: A new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for the treatment of prostate cancer
199. Novel non-steroidal inhibitors of cytochrome P450 (17α) (17α-hydroxylase/C17-20 lyase), YM 116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats
200. Pyridyl substituted benzocycloalkenes - New inhibitors of 17-alpha-hydroxylase-17,20-lyase (P450 17-alpha)
201. Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid
202. Esters of 3-pyridylacetic acid that combine potent inhibition of 17-alpha-hydroxylase C-17,C-20-lyase (cytochrome P450-alpha) with resistance to esterase hydrolysis
203. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450 (17 alpha) inhibitors
204. 3- and 4-pyridylalkyl-adamantanecarboxylates: Inhibitors of human cytochrome P450 (17 alpha) (17 alpha-hydroxylase/C-17,C-20-lyase): Potential nonsteroidal agents for the treatment of prostatic cancer
205. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450 (17 alpha) inhibitors
206. Steroidal androgen biosynthesis inhibitors
207. 20-Amino and 20,21-aziridinyl pregnene steroids: Development of potent inhibitors of 17 alpha-hydroxylase C17,C20-lyase (P450 17)
208. The impact of aromatase mechanism on other P450s
209. Pharmacology of novel steroidal inhibitors of cytochrome P450 (17-alpha) (17-alpha-hydroxylase C17-20 lyase)
210. The 16,17-double bond is needed for irreversible inhibition of human cytochrome P450 (17 alpha) by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3-beta-ol) and related steroidal inhibitors
211. Novel 17-azoyl steroids, potent inhibitors of human cytochrome 17-alpha-hydroxylase-C-17, C-20-lyase (P450 (17 alpha)): Potential agents for the treatment of prostate cancer
212. 17-Beta-(cyclopropylamino)-androst-5-en-3-beta-ol, a selective mechanism-based inhibitor of cytochrome P450 17-alpha (steroid 17-alpha hydroxylase-C-17,C-20 lyase)